Bright Minds Biosciences (DRUG) Expected to Release Earnings on Thursday

Bright Minds Biosciences (NASDAQ:DRUG) is anticipated to announce its Q3 2026 results before the market opens on Thursday, August 13th. Analysts expect Bright Minds Biosciences to announce earnings of ($1.2831) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, August 20, 2026 at 4:00 PM ET.

Bright Minds Biosciences (NASDAQ:DRUG) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.06. On average, analysts expect Bright Minds Biosciences to post $-5 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Bright Minds Biosciences Trading Down 0.7%

Shares of NASDAQ DRUG opened at $80.25 on Wednesday. The stock has a market cap of $780.83 million, a PE ratio of -32.89 and a beta of -5.27. Bright Minds Biosciences has a 12-month low of $38.00 and a 12-month high of $123.75. The company has a 50-day moving average of $70.39 and a 200 day moving average of $77.31.

Analyst Ratings Changes

Several research analysts have recently weighed in on DRUG shares. Piper Sandler restated an “overweight” rating and set a $220.00 target price (up from $190.00) on shares of Bright Minds Biosciences in a report on Wednesday, May 20th. Wall Street Zen upgraded Bright Minds Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 4th. HC Wainwright reissued a “buy” rating and set a $145.00 price objective on shares of Bright Minds Biosciences in a research note on Monday, June 1st. Finally, Zacks Research upgraded Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $143.83.

Institutional Trading of Bright Minds Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in DRUG. Vivo Capital LLC increased its stake in Bright Minds Biosciences by 99.4% during the third quarter. Vivo Capital LLC now owns 501,617 shares of the company’s stock worth $30,428,000 after acquiring an additional 250,045 shares during the last quarter. MPM Bioimpact LLC acquired a new position in shares of Bright Minds Biosciences in the 4th quarter valued at $17,961,000. Balyasny Asset Management L.P. purchased a new position in shares of Bright Minds Biosciences during the 3rd quarter worth $11,339,000. Millennium Management LLC grew its holdings in shares of Bright Minds Biosciences by 376.9% during the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company’s stock worth $6,946,000 after purchasing an additional 152,178 shares during the period. Finally, Ikarian Capital LLC increased its position in shares of Bright Minds Biosciences by 933.1% during the 4th quarter. Ikarian Capital LLC now owns 159,421 shares of the company’s stock worth $12,441,000 after purchasing an additional 143,990 shares during the last quarter. Institutional investors and hedge funds own 40.52% of the company’s stock.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.